{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:10:27Z","timestamp":1792822227910,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Agents targeting colchicine-binding pocket usually show a minimal drug-resistance issue, albeit often associated with high toxicity. Chalcone-based compounds, which may bind to colchicine-binding site, are found in many edible fruits, suggesting that they can be effective drugs with less toxicity. Therefore, we synthesized and examined 24 quinolone chalcone compounds, from which we identified ((E)-3-(3-(2-Methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one) (CTR-17) and ((E)-6-Methoxy-3-(3-(2-methoxyphenyl)-3-oxoprop-1-enyl) quinolin-2(1H)-one) (CTR-20) as promising leads. In particular, CTR-20 was effective against 65 different cancer cell lines originated from 12 different tissues, largely in a cancer cell-specific manner. We found that both CTR-17 and CTR-20 reversibly bind to the colchicine-binding pocket on \u03b2-tubulin. Interestingly however, both the CTRs were highly effective against multidrug-resistant cancer cells while colchicine, paclitaxel and vinblastine were not. Our study with CTR-20 showed that it overcomes multidrug-resistance through its ability to impede MRP1 function while maintaining strong inhibition against microtubule activity. Data from mice engrafted with the MDA-MB-231 triple-negative breast cancer cells showed that both CTR-17 and CTR-20 possess strong anticancer activity, alone or in combination with paclitaxel, without causing any notable side effects. Together, our data demonstrates that both the CTRs can be effective and safe drugs against many different cancers, especially against multidrug-resistant tumors.<\/jats:p>","DOI":"10.1038\/s41598-017-10972-0","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T18:34:22Z","timestamp":1503686062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function"],"prefix":"10.1038","volume":"7","author":[{"given":"I. Kalhari","family":"Lindamulage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yen","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrabose","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Knockleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"10972_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9, 790\u2013803, doi:10.1038\/nrd3253 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"10972_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/157488406775268200","volume":"1","author":"IE Kuppens","year":"2006","unstructured":"Kuppens, I. E. Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 1, 57\u201370 (2006).","journal-title":"Curr Clin Pharmacol"},{"key":"10972_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/iub.42","volume":"60","author":"P Singh","year":"2008","unstructured":"Singh, P., Rathinasamy, K., Mohan, R. & Panda, D. Microtubule assembly dynamics: an attractive target for anticancer drugs. IUBMB Life 60, 368\u2013375, doi:10.1002\/iub.42 (2008).","journal-title":"IUBMB Life"},{"key":"10972_CR4","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","volume":"29","author":"Y Lu","year":"2012","unstructured":"Lu, Y., Chen, J., Xiao, M., Li, W. & Miller, D. D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 29, 2943\u20132971, doi:10.1007\/s11095-012-0828-z (2012).","journal-title":"Pharm Res"},{"key":"10972_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2174\/1871520616666160219161921","volume":"16","author":"X Wu","year":"2016","unstructured":"Wu, X., Wang, Q. & Li, W. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site. Anticancer Agents Med Chem 16, 1325\u20131338 (2016).","journal-title":"Anticancer Agents Med Chem"},{"key":"10972_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/IJWH.S7012","volume":"2","author":"S Kumar","year":"2010","unstructured":"Kumar, S. et al. Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health 2, 411\u2013427, doi:10.2147\/IJWH.S7012 (2010).","journal-title":"Int J Womens Health"},{"key":"10972_CR7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1634\/theoncologist.3-2-86","volume":"3","author":"DL Ornstein","year":"1998","unstructured":"Ornstein, D. L. & Rigas, J. R. Taxotere: Clinical Trials in Non-Small Cell Lung Cancer. Oncologist 3, 86\u201393 (1998).","journal-title":"Oncologist"},{"key":"10972_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jvim.12006","volume":"27","author":"EL Krick","year":"2013","unstructured":"Krick, E. L., Cohen, R. B., Gregor, T. P., Salah, P. C. & Sorenmo, K. U. Prospective clinical trial to compare vincristine and vinblastine in a COP-based protocol for lymphoma in cats. J Vet Intern Med 27, 134\u2013140, doi:10.1111\/jvim.12006 (2013).","journal-title":"J Vet Intern Med"},{"key":"10972_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/bse0500179","volume":"50","author":"AJ Slot","year":"2011","unstructured":"Slot, A. J., Molinski, S. V. & Cole, S. P. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem 50, 179\u2013207, doi:10.1042\/bse0500179 (2011).","journal-title":"Essays Biochem"},{"issue":"Suppl","key":"10972_CR10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s002800051053","volume":"40","author":"V Ling","year":"1997","unstructured":"Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40(Suppl), S3\u20138 (1997).","journal-title":"Cancer Chemother Pharmacol"},{"key":"10972_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1517\/14622416.2.1.51","volume":"2","author":"R Kerb","year":"2001","unstructured":"Kerb, R., Hoffmeyer, S. & Brinkmann, U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2, 51\u201364, doi:10.1517\/14622416.2.1.51 (2001).","journal-title":"Pharmacogenomics"},{"key":"10972_CR12","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","volume":"22","author":"L Doyle","year":"2003","unstructured":"Doyle, L. & Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340\u20137358, doi:10.1038\/sj.onc.1206938 (2003).","journal-title":"Oncogene"},{"key":"10972_CR13","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/cancers7040897","volume":"7","author":"AM Barbuti","year":"2015","unstructured":"Barbuti, A. M. & Chen, Z. S. Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. Cancers (Basel) 7, 2360\u20132371, doi:10.3390\/cancers7040897 (2015).","journal-title":"Cancers (Basel)"},{"key":"10972_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009033333754","volume":"3","author":"RZ Yusuf","year":"2003","unstructured":"Yusuf, R. Z., Duan, Z., Lamendola, D. E., Penson, R. T. & Seiden, M. V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3, 1\u201319 (2003).","journal-title":"Curr Cancer Drug Targets"},{"key":"10972_CR15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1078-0432.298.11.1","volume":"11","author":"S Mozzetti","year":"2005","unstructured":"Mozzetti, S. et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11, 298\u2013305 (2005).","journal-title":"Clin Cancer Res"},{"key":"10972_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","volume":"9","author":"P Seve","year":"2008","unstructured":"Seve, P. & Dumontet, C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9, 168\u2013175, doi:10.1016\/S1470-2045(08)70029-9 (2008).","journal-title":"Lancet Oncol"},{"key":"10972_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","volume":"102","author":"C Stengel","year":"2010","unstructured":"Stengel, C. et al. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102, 316\u2013324, doi:10.1038\/sj.bjc.6605489 (2010).","journal-title":"Br J Cancer"},{"key":"10972_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1568011053352569","volume":"5","author":"J Zhou","year":"2005","unstructured":"Zhou, J. & Giannakakou, P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5, 65\u201371 (2005).","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10972_CR19","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.2174\/0929867322666150114163732","volume":"22","author":"YT Ji","year":"2015","unstructured":"Ji, Y. T., Liu, Y. N. & Liu, Z. P. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments. Curr Med Chem 22, 1348\u20131360 (2015).","journal-title":"Curr Med Chem"},{"key":"10972_CR20","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1016\/j.bmc.2009.09.044","volume":"17","author":"S Ducki","year":"2009","unstructured":"Ducki, S. et al. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg Med Chem 17, 7711\u20137722, doi:10.1016\/j.bmc.2009.09.044 (2009).","journal-title":"Bioorg Med Chem"},{"key":"10972_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1021\/jm049444m","volume":"48","author":"S Ducki","year":"2005","unstructured":"Ducki, S., Mackenzie, G., Lawrence, N. J. & Snyder, J. P. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly. J Med Chem 48, 457\u2013465, doi:10.1021\/jm049444m (2005).","journal-title":"J Med Chem"},{"key":"10972_CR22","first-page":"309","volume":"5","author":"JA Hadfield","year":"2003","unstructured":"Hadfield, J. A., Ducki, S., Hirst, N. & McGown, A. T. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 5, 309\u2013325 (2003).","journal-title":"Prog Cell Cycle Res"},{"key":"10972_CR23","first-page":"135","volume":"15","author":"NJ Lawrence","year":"2000","unstructured":"Lawrence, N. J., McGown, A. T., Ducki, S. & Hadfield, J. A. The interaction of chalcones with tubulin. Anticancer Drug Des 15, 135\u2013141 (2000).","journal-title":"Anticancer Drug Des"},{"key":"10972_CR24","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.1021\/bi00160a024","volume":"31","author":"V Peyrot","year":"1992","unstructured":"Peyrot, V. et al. Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: equilibrium studies. Biochemistry 31, 11125\u201311132 (1992).","journal-title":"Biochemistry"},{"key":"10972_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/1568009614666140122160515","volume":"14","author":"DD Jandial","year":"2014","unstructured":"Jandial, D. D. et al. Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets 14, 181\u2013200 (2014).","journal-title":"Curr Cancer Drug Targets"},{"key":"10972_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biopha.2011.11.013","volume":"66","author":"VR Solomon","year":"2012","unstructured":"Solomon, V. R. & Lee, H. Anti-breast cancer activity of heteroaryl chalcone derivatives. Biomed Pharmacother 66, 213\u2013220, doi:10.1016\/j.biopha.2011.11.013 (2012).","journal-title":"Biomed Pharmacother"},{"key":"10972_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621\u2013681, doi:10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol Rev"},{"key":"10972_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30, 488\u2013496, doi:10.1200\/JCO.2011.34.7898 (2012).","journal-title":"J Clin Oncol"},{"key":"10972_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044311","volume":"7","author":"A Rai","year":"2012","unstructured":"Rai, A., Surolia, A. & Panda, D. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics. PLoS One 7, e44311, doi:10.1371\/journal.pone.0044311 (2012).","journal-title":"PLoS One"},{"key":"10972_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075182","volume":"8","author":"JB Venghateri","year":"2013","unstructured":"Venghateri, J. B., Gupta, T. K., Verma, P. J., Kunwar, A. & Panda, D. Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. PLoS One 8, e75182, doi:10.1371\/journal.pone.0075182 (2013).","journal-title":"PLoS One"},{"key":"10972_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004881","volume":"4","author":"C Zhang","year":"2009","unstructured":"Zhang, C. et al. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One 4, e4881, doi:10.1371\/journal.pone.0004881 (2009).","journal-title":"PLoS One"},{"key":"10972_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.bcp.2012.06.008","volume":"84","author":"KK Gireesh","year":"2012","unstructured":"Gireesh, K. K., Rashid, A., Chakraborti, S., Panda, D. & Manna, T. CIL-102 binds to tubulin at colchicine binding site and triggers apoptosis in MCF-7 cells by inducing monopolar and multinucleated cells. Biochem Pharmacol 84, 633\u2013645, doi:10.1016\/j.bcp.2012.06.008 (2012).","journal-title":"Biochem Pharmacol"},{"key":"10972_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1432-1033.1993.tb18195.x","volume":"216","author":"A Bhattacharyya","year":"1993","unstructured":"Bhattacharyya, A., Bhattacharyya, B. & Roy, S. A study of colchicine tubulin complex by donor quenching of fluorescence energy transfer. Eur J Biochem 216, 757\u2013761 (1993).","journal-title":"Eur J Biochem"},{"key":"10972_CR34","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1073\/pnas.71.7.2627","volume":"71","author":"B Bhattacharyya","year":"1974","unstructured":"Bhattacharyya, B. & Wolff, J. Promotion of fluorescence upon binding of colchicine to tubulin. Proc Natl Acad Sci USA 71, 2627\u20132631 (1974).","journal-title":"Proc Natl Acad Sci USA"},{"key":"10972_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/bj1370143","volume":"137","author":"A Cornish-Bowden","year":"1974","unstructured":"Cornish-Bowden, A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137, 143\u2013144 (1974).","journal-title":"Biochem J"},{"key":"10972_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-242","volume":"9","author":"A Boumendjel","year":"2009","unstructured":"Boumendjel, A. et al. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer 9, 242, doi:10.1186\/1471-2407-9-242 (2009).","journal-title":"BMC Cancer"},{"key":"10972_CR37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","volume":"299","author":"JW Polli","year":"2001","unstructured":"Polli, J. W. et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299, 620\u2013628 (2001).","journal-title":"J Pharmacol Exp Ther"},{"key":"10972_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ijc.20140","volume":"110","author":"K Klappe","year":"2004","unstructured":"Klappe, K., Hinrichs, J. W., Kroesen, B. J., Sietsma, H. & Kok, J. W. MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 110, 511\u2013522, doi:10.1002\/ijc.20140 (2004).","journal-title":"Int J Cancer"},{"key":"10972_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1535-6108(03)00302-7","volume":"4","author":"HJ Shin","year":"2003","unstructured":"Shin, H. J. et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 4, 483\u2013497 (2003).","journal-title":"Cancer Cell"},{"key":"10972_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375\u2013388, doi:10.1016\/j.ccr.2006.10.006 (2006).","journal-title":"Cancer Cell"},{"key":"10972_CR41","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11, 1149\u20131159, doi:10.1016\/S1470-2045(10)70261-8 (2010).","journal-title":"Lancet Oncol"},{"key":"10972_CR42","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg, C. J. & Cory, S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121, 2285\u20132288, doi:10.1182\/blood-2013-01-475855 (2013).","journal-title":"Blood"},{"key":"10972_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0224-3","volume":"8","author":"S Cang","year":"2015","unstructured":"Cang, S., Iragavarapu, C., Savooji, J., Song, Y. & Liu, D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol 8, 129, doi:10.1186\/s13045-015-0224-3 (2015).","journal-title":"J Hematol Oncol"},{"key":"10972_CR44","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs, S. et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124, 3738\u20133747, doi:10.1182\/blood-2014-05-574566 (2014).","journal-title":"Blood"},{"key":"10972_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/943648","volume":"2014","author":"M Vogler","year":"2014","unstructured":"Vogler, M. Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med 2014, 943648, doi:10.1155\/2014\/943648 (2014).","journal-title":"Adv Med"},{"key":"10972_CR46","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/cdd.2014.37","volume":"21","author":"S Colak","year":"2014","unstructured":"Colak, S. et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ 21, 1170\u20131177, doi:10.1038\/cdd.2014.37 (2014).","journal-title":"Cell Death Differ"},{"key":"10972_CR47","first-page":"1449","volume":"149","author":"M Krajewska","year":"1996","unstructured":"Krajewska, M. et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 149, 1449\u20131457 (1996).","journal-title":"Am J Pathol"},{"key":"10972_CR48","first-page":"2422","volume":"56","author":"M Krajewska","year":"1996","unstructured":"Krajewska, M. et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56, 2422\u20132427 (1996).","journal-title":"Cancer Res"},{"key":"10972_CR49","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S0022-5347(01)63614-0","volume":"159","author":"EJ Kirsh","year":"1998","unstructured":"Kirsh, E. J., Baunoch, D. A. & Stadler, W. M. Expression of bcl-2 and bcl-X in bladder cancer. J Urol 159, 1348\u20131353 (1998).","journal-title":"J Urol"},{"key":"10972_CR50","doi-asserted-by":"publisher","unstructured":"Kondo, S. et al. Over-expression of bcl-xL gene in human gastric adenomas and carcinomas. Int J Cancer 68, 727\u2013730, doi:10.1002\/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5 (1996).","DOI":"10.1002\/(SICI)1097-0215"},{"key":"10972_CR51","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905, doi:10.1038\/nature08822 (2010).","journal-title":"Nature"},{"key":"10972_CR52","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29, 909\u2013916, doi:10.1200\/JCO.2010.31.6208 (2011).","journal-title":"J Clin Oncol"},{"key":"10972_CR53","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/S0021-9258(18)89437-6","volume":"260","author":"D Bonne","year":"1985","unstructured":"Bonne, D., Heusele, C., Simon, C. & Pantaloni, D. 4\u2032,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 260, 2819\u20132825 (1985).","journal-title":"J Biol Chem"},{"key":"10972_CR54","doi-asserted-by":"publisher","first-page":"17896","DOI":"10.1074\/jbc.M109.096578","volume":"285","author":"N Tokesi","year":"2010","unstructured":"Tokesi, N. et al. TPPP\/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J Biol Chem 285, 17896\u201317906, doi:10.1074\/jbc.M109.096578 (2010).","journal-title":"J Biol Chem"},{"key":"10972_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.CCR-05-0229","volume":"12","author":"GS Huang","year":"2006","unstructured":"Huang, G. S. et al. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 12, 298\u2013304, doi:10.1158\/1078-0432.CCR-05-0229 (2006).","journal-title":"Clin Cancer Res"},{"key":"10972_CR56","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1158\/0008-5472.CAN-14-3370","volume":"75","author":"S Pundir","year":"2015","unstructured":"Pundir, S., Vu, H. Y., Solomon, V. R., McClure, R. & Lee, H. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer Res 75, 4164\u20134175, doi:10.1158\/0008-5472.CAN-14-3370 (2015).","journal-title":"Cancer Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10972-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:12:30Z","timestamp":1750821150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10972-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["10972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-10972-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]},"assertion":[{"value":"5 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10298"}}